182 related articles for article (PubMed ID: 34616589)
1. CD34
Van der Meer JMR; de Jonge PKJD; van der Waart AB; Geerlings AC; Moonen JP; Brummelman J; de Klein J; Vermeulen MC; Maas RJA; Schaap NPM; Hoogstad-van Evert JS; Ottevanger PB; Jansen JH; Hobo W; Dolstra H
Oncoimmunology; 2021; 10(1):1981049. PubMed ID: 34616589
[TBL] [Abstract][Full Text] [Related]
2. IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34
Van der Meer JMR; Maas RJA; Guldevall K; Klarenaar K; de Jonge PKJD; Evert JSH; van der Waart AB; Cany J; Safrit JT; Lee JH; Wagena E; Friedl P; Önfelt B; Massuger LF; Schaap NPM; Jansen JH; Hobo W; Dolstra H
Cancer Immunol Immunother; 2021 May; 70(5):1305-1321. PubMed ID: 33140189
[TBL] [Abstract][Full Text] [Related]
3. Decitabine enhances targeting of AML cells by CD34
Cany J; Roeven MWH; Hoogstad-van Evert JS; Hobo W; Maas F; Franco Fernandez R; Blijlevens NMA; van der Velden WJ; Huls G; Jansen JH; Schaap NPM; Dolstra H
Blood; 2018 Jan; 131(2):202-214. PubMed ID: 29138222
[TBL] [Abstract][Full Text] [Related]
4. TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer.
Maas RJ; Hoogstad-van Evert JS; Van der Meer JM; Mekers V; Rezaeifard S; Korman AJ; de Jonge PK; Cany J; Woestenenk R; Schaap NP; Massuger LF; Jansen JH; Hobo W; Dolstra H
Oncoimmunology; 2020 Nov; 9(1):1843247. PubMed ID: 33224630
[TBL] [Abstract][Full Text] [Related]
5. Natural killer cells generated from cord blood hematopoietic progenitor cells efficiently target bone marrow-residing human leukemia cells in NOD/SCID/IL2Rg(null) mice.
Cany J; van der Waart AB; Tordoir M; Franssen GM; Hangalapura BN; de Vries J; Boerman O; Schaap N; van der Voort R; Spanholtz J; Dolstra H
PLoS One; 2013; 8(6):e64384. PubMed ID: 23755121
[TBL] [Abstract][Full Text] [Related]
6. Combined IL-15 and IL-12 drives the generation of CD34
Cany J; van der Waart AB; Spanholtz J; Tordoir M; Jansen JH; van der Voort R; Schaap NM; Dolstra H
Oncoimmunology; 2015 Jul; 4(7):e1017701. PubMed ID: 26140247
[TBL] [Abstract][Full Text] [Related]
7. Umbilical cord blood CD34
Hoogstad-van Evert JS; Cany J; van den Brand D; Oudenampsen M; Brock R; Torensma R; Bekkers RL; Jansen JH; Massuger LF; Dolstra H
Oncoimmunology; 2017; 6(8):e1320630. PubMed ID: 28919991
[TBL] [Abstract][Full Text] [Related]
8. IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer.
Felices M; Chu S; Kodal B; Bendzick L; Ryan C; Lenvik AJ; Boylan KLM; Wong HC; Skubitz APN; Miller JS; Geller MA
Gynecol Oncol; 2017 Jun; 145(3):453-461. PubMed ID: 28236454
[TBL] [Abstract][Full Text] [Related]
9. Immunodeficient mouse strains display marked variability in growth of human melanoma lung metastases.
Carreno BM; Garbow JR; Kolar GR; Jackson EN; Engelbach JA; Becker-Hapak M; Carayannopoulos LN; Piwnica-Worms D; Linette GP
Clin Cancer Res; 2009 May; 15(10):3277-86. PubMed ID: 19447870
[TBL] [Abstract][Full Text] [Related]
10. Attenuation of the glucocorticoid response during Ad5IL-12 adenovirus vector treatment enhances natural killer cell-mediated killing of MHC class I-negative LNCaP prostate tumors.
Raja Gabaglia C; Diaz de Durana Y; Graham FL; Gauldie J; Sercarz EE; Braciak TA
Cancer Res; 2007 Mar; 67(5):2290-7. PubMed ID: 17332360
[TBL] [Abstract][Full Text] [Related]
11. Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice.
Siegler U; Kalberer CP; Nowbakht P; Sendelov S; Meyer-Monard S; Wodnar-Filipowicz A
Leukemia; 2005 Dec; 19(12):2215-22. PubMed ID: 16224486
[TBL] [Abstract][Full Text] [Related]
12. Ex vivo-expanded NK cells from blood and ascites of ovarian cancer patients are cytotoxic against autologous primary ovarian cancer cells.
Nham T; Poznanski SM; Fan IY; Shenouda MM; Chew MV; Lee AJ; Vahedi F; Karimi Y; Butcher M; Lee DA; Hirte H; Ashkar AA
Cancer Immunol Immunother; 2018 Apr; 67(4):575-587. PubMed ID: 29299659
[TBL] [Abstract][Full Text] [Related]
13. Ovarian cancer treatment and natural killer cell-based immunotherapy.
Fan Z; Han D; Fan X; Zhao L
Front Immunol; 2023; 14():1308143. PubMed ID: 38187402
[TBL] [Abstract][Full Text] [Related]
14. TEM8 Tri-specific Killer Engager binds both tumor and tumor stroma to specifically engage natural killer cell anti-tumor activity.
Kaminski MF; Bendzick L; Hopps R; Kauffman M; Kodal B; Soignier Y; Hinderlie P; Walker JT; Lenvik TR; Geller MA; Miller JS; Felices M
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36162918
[TBL] [Abstract][Full Text] [Related]
15. Harnessing natural killer cells for the treatment of ovarian cancer.
Hoogstad-van Evert JS; Bekkers R; Ottevanger N; Jansen JH; Massuger L; Dolstra H
Gynecol Oncol; 2020 Jun; 157(3):810-816. PubMed ID: 32268953
[TBL] [Abstract][Full Text] [Related]
16. Anti-ovarian tumor response of donor peripheral blood mononuclear cells is due to infiltrating cytotoxic NK cells.
Pandey V; Oyer JL; Igarashi RY; Gitto SB; Copik AJ; Altomare DA
Oncotarget; 2016 Feb; 7(6):7318-28. PubMed ID: 26802025
[TBL] [Abstract][Full Text] [Related]
17. Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model.
Geller MA; Knorr DA; Hermanson DA; Pribyl L; Bendzick L; McCullar V; Miller JS; Kaufman DS
Cytotherapy; 2013 Oct; 15(10):1297-306. PubMed ID: 23993303
[TBL] [Abstract][Full Text] [Related]
18. Human NK cells of mice with reconstituted human immune system components require preactivation to acquire functional competence.
Strowig T; Chijioke O; Carrega P; Arrey F; Meixlsperger S; Rämer PC; Ferlazzo G; Münz C
Blood; 2010 Nov; 116(20):4158-67. PubMed ID: 20671122
[TBL] [Abstract][Full Text] [Related]
19. Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells.
Sommaggio R; Cappuzzello E; Dalla Pietà A; Tosi A; Palmerini P; Carpanese D; Nicolè L; Rosato A
Oncoimmunology; 2020 Jun; 9(1):1777046. PubMed ID: 32923140
[TBL] [Abstract][Full Text] [Related]
20. Human NK cell development in NOD/SCID mice receiving grafts of cord blood CD34+ cells.
Kalberer CP; Siegler U; Wodnar-Filipowicz A
Blood; 2003 Jul; 102(1):127-35. PubMed ID: 12637322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
